 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > AVANT Immunotherapeutics, Inc.
 |
AVANT Immunotherapeutics, Inc. |
 |
 |
 |
PROFILE |
 |
Development-stage AVANT Immunotherapeutics develops treatments for cardiovascular, pulmonary, and autoimmune disorders, as well as infectious diseases and organ transplant rejection, caused by malfunctions of the body's natural defense systems. AVANT's leading therapeutic compound is TP10, which is being developed as a post-transplant, cardiac surgery, and heart attack therapeutic. The firm is also developing a cholesterol-lowering vaccine against atherosclerosis and vaccines for conditions usually encountered by travelers, such as cholera, dysentery, and others. AVANT bought vaccine developer Megan Health and has teamed with Pfizer to develop animal vaccines based on Megan's technology.
COMPETITION |
 |
Alexion Pharmaceuticals, Inc. (ALXN)
Aviron (AVIR)
MedImmune, Inc. (MEDI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.80
1-Yr. Sales Growth: (46.7)%
Employees: 66
Revenue per employee: $12,121.21
KEY PEOPLE |
 |
Una S. Ryan
CEO
Avery W. Catlin
CFO
CONTACT INFO |
 |
119 4th Ave.
Needham, MA 02494
US
Phone: 781-433-0771
Fax: 781-433-0262
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |